Development of a multifunctional biomaterial patch for buccal delivery of peptide-analogue treatments

Period: 01/01/2023 – 31/12/2026

Funding scheme: HORIZON-RIA – HORIZON Research and Innovation Actions
Coordination: University College Dublin, National University of Ireland, Dublin
Website: https://cordis.europa.eu/project/id/101091765 | https://buccal-pep.eu/project/


Oral delivery of peptide macromolecules represents significant challenges for pharmaceutical research, including low bioavailability, dosage control and undesirable food interactions. The intention of the EU-funded BUCCAL-PEP project is to develop a technological platform for oromucosal delivery suitable for a broad range of peptide-analogue therapies. To this end, the consortium will develop a multifunctional biomaterial patch to allow buccal (in the cheek) delivery of therapies using an integration of permeation enhancers with biomaterials and peptide analogues. The objective is to design, select and manufacture a lead product for the treatment of type 2 diabetes as a showcase indication and validate its performance in vivo in large animal models.



University of Ireland | Technical University of Denmark | Charité- Medical University of Berlin | AdhexPharmaNovo Nordisk |  Catalyse B. V. | Cambridge Innovation Technologies Consulting Ltd.University of Aveiro